VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:
\n\u2022 have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
\n\u2022 are metastatic or where surgical resection is likely to result in severe morbidity, and
\n\u2022 have no satisfactory alternative treatments or that have progressed following treatment.
\nThis indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.<\/p>\n
Larotrectinib Capsules is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed. If Larotrectinib Capsules are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN.<\/strong>\u00a0For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query.\u00a0Like 1. How to get access in in India. 2. Medicine Price. 3. Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia. 4. Ensuring 100% transparency.\u00a0<\/strong><\/p>\n Larotrectinib Capsules can be made available to patients, doctors, and hospitals in Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.<\/p>\n To receive comprehensive support, please call us at\u00a09811747774<\/a>,\u00a09891296838<\/a>\u00a0or WhatsApp at\u00a09811747774<\/a>,\u00a09891296838\u00a0<\/a>or email us at\u00a0info@indianpharmanetwork.co.in\u00a0<\/a> for Vitrakvi (larotrectinib) Capsules price in India.<\/strong><\/p>\n Note:<\/strong><\/em> Vitrakvi (larotrectinib) is a medication used for the treatment of patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.<\/p>\n Disease Indications-Solid Tumor If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import \u201clarotrectinib capsules\u201d based on the information you provide.<\/strong><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"VITRAKVI 25 mg hard capsules<\/h2>\n
Facts about larotrectinib capsules<\/h4>\n
\nManufacturer-Bayer
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n